glp-1/gip agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research GIP Receptor Agonism Attenuates GLP-1

In Parkinsons disease, early trials of exenatide and lixisenatide produced encouraging signals, including motor benefits that appeared to persist after treatment stopped

Nobiletin showed no obvious cytotoxicity in vivo (0.05% dietary concentration for 320 weeks) or in vitro (effective concentration 40 M), and cells resumed normal growth after withdrawal, with safety superior to existing chemotherapeutic agents (Goh et al., 2019)

Adems, es suplementado con cido pantotnico

(PubMed) Johnson JL, Duran M

10.3389/fendo.2022.910256 78

For both, the rule is the same: judge by the tape measure and side-profile photos, not the scale